ストックスクリーナーアプリを入手
0.9235
2.69%
0.0242
アフターアワーズ：
.92
-0.0035
-0.38%
前日終値:
$0.8993
開ける：
$0.92
24時間の取引高:
325.73K
Relative Volume:
0.73
時価総額：
$110.31M
収益：
-
当期純損益:
$-198.64M
株価収益率:
-0.5736
EPS:
-1.61
ネットキャッシュフロー:
$-173.78M
1週間 パフォーマンス:
+1.83%
1か月 パフォーマンス:
-2.84%
6か月 パフォーマンス:
-61.84%
1年 パフォーマンス:
-39.24%
1日の値動き範囲:
$0.90
$0.94
1週間の範囲:
$0.89
$0.9648
52週間の値動き範囲:
$0.8116
$5.195
Invivyd Inc Stock (IVVD) Company Profile
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
Invivyd Inc (IVVD) 最新ニュース
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Guggenheim upgrades Invivyd Inc (IVVD) stock to a Buy - Knox Daily
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 - The Manila Times
Point72 Asia Singapore Pte. Ltd. Sells 40,079 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data - The Manila Times
Invivyd Inc: Rising -81.14% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Invivyd Inc [IVVD] Records 200-Day SMA of $2.5044 - Knox Daily
Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Take off with Invivyd Inc (IVVD): Get ready for trading - SETE News
Invivyd reports stable pemivibart potency against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com
Invivyd Inc (IVVD) is a good investment, but the stock may be undervalued - US Post News
Investor’s Toolkit: Key Ratios for Assessing Invivyd Inc (IVVD)’s Performance - The Dwinnex
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - ForexTV.com
Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA - StreetInsider.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated - Daily Guardian Canada
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Global BMI Index - Marketscreener.com
Acadian Asset Management LLC Acquires 474,301 Shares of Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug - Law360
Invivyd Inc (IVVD)’s highs and lows: A closer look at its stock price fluctuations - US Post News
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate - Yahoo Finance
IVVD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
A company insider recently sold 112,381 shares of Invivyd Inc [IVVD]. Should You Sale? - Knox Daily
When Will Invivyd, Inc. (NASDAQ:IVVD) Breakeven? - Simply Wall St
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 - ForexTV.com
Enphase, First Solar, FedEx, Progyny, Steelcase, and More Stock Market Movers - Barron's
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Adagio Therapeutics Stock Hits 52-Week Low at $0.84 Amid Challenges - Investing.com
Invivyd Inc [IVVD] stock for 186,575 USD was sold by MCGUIRE TERRANCE - Knox Daily
Invivyd to Participate in Upcoming Investor Conferences - Yahoo Finance UK
Invivyd begins Phase 1 trial for new COVID-19 antibody - Investing.com India
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ - ForexTV.com
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation ... - Post Register
Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright - Defense World
Invivyd shares hold Buy as new data and updates bolster COVID-19 strategy - Investing.com
Ratio Examination: Invivyd Inc (IVVD)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest - ForexTV.com
Analytical Overview: Invivyd Inc (IVVD)’s Ratios Tell a Financial Story - The Dwinnex
Invivyd shares hold Buy rating with price target post-data By Investing.com - Investing.com Australia
Invivyd shares hold Buy rating with price target post-data - Investing.com India
Recent Insider Activity Could Benefit Invivyd Inc (IVVD) - Knox Daily
Views of Wall Street’s Leading Experts on Invivyd Inc - SETE News
Invivyd’s (IVVD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
Invivyd Inc (IVVD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Adimab, LLC | 10% Owner |
Jan 19 '24 |
Sale |
3.95 |
5,000,000 |
19,750,000 |
21,687,906 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):